Successfully Treating Kaposi Sarcoma: Robert Yarchoan, MD

Robert Yarchoan, MD, Chief of the HIV and AIDS Malignancy Branch at the National Cancer Institute (NCI), recently spoke with i3 Health about the approval of pomalidomide (Pomalyst®, Celgene) for Kaposi sarcoma in patients with and without HIV. In this second installment of his interview, Dr. Yarchoan shares valuable advice with oncologists as they seek to enhance outcomes and treatment experiences for patients with Kaposi sarcoma. What advice can you share with oncologists treating patients with...
Continue reading

Pomalidomide for Kaposi Sarcoma: Robert Yarchoan, MD

The FDA's recent accelerated approval of pomalidomide (Pomalyst®, Celgene) for Kaposi sarcoma in patients with and without HIV marked the first approval for this cancer in over 20 years. In this interview with i3 Health, Robert Yarchoan, MD, Chief of the HIV and AIDS Malignancy Branch at the National Cancer Institute (NCI) and principal investigator of the phase 1/2 Study 12-C-0047, which served as the basis for the approval, discusses pomalidomide's efficacy and safety, as well as additional re...
Continue reading

Kaposi Sarcoma: Pomalidomide Granted Accelerated Approval

In the first new drug approval for Kaposi sarcoma in over 20 years, the FDA has expanded the indication for pomalidomide (Pomalyst®, Celgene) in an accelerated approval, both for HIV-negative patients with Kaposi sarcoma and for patients with AIDS-related Kaposi sarcoma resistant to highly active antiretroviral therapy (HAART). The approval was based on data from Study 12-C-0047 (NCT01495598), an open-label, single-arm phase 1/2 trial in which 28 patients with Kaposi sarcoma, including 18 who we...
Continue reading

How Does Cancer Treatment Affect Immune Health in HIV Patients?

In people with HIV and cancer, antiretroviral therapy is often used during cancer treatment to mitigate complications of HIV progression. However, questions regarding long-term effects of cancer treatment in this patient population remain, such as the immunosuppressive effects on HIV RNA level and CD4 count, which are indicators of a patient's morbidity and mortality. Therefore, scientists sought to measure the link between these biomarkers and associated mortality after cancer treatment. They p...
Continue reading

Higher Cancer Mortality Rates in HIV-Positive Older Patients

According to researchers, the disparity in cancer mortality rates between older patients with both human immunodeficiency virus (HIV) and cancer and older patients who have cancer but not HIV is due to more than the suboptimal cancer treatment given to those with HIV. It has previously been established that patients with both HIV and cancer have higher rates of cancer-specific mortality in comparison to other patients with cancer, yet the cause of this discrepancy has not been fully explained. "...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.